Bruker (NASDAQ:BRKR – Get Free Report) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $2.36-2.41 for the period, compared to the consensus estimate of $2.59. The company issued revenue guidance of $3.34-3.37 billion, compared to the consensus revenue estimate of $3.40 billion. Bruker also updated its FY 2024 guidance to 2.360-2.410 EPS.
Wall Street Analyst Weigh In
BRKR has been the subject of several analyst reports. Wells Fargo & Company cut their price target on Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a report on Wednesday. Citigroup dropped their target price on Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday. Barclays decreased their price target on Bruker from $75.00 to $69.00 and set an “overweight” rating on the stock in a research note on Wednesday. Wolfe Research downgraded shares of Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. Finally, TD Cowen decreased their target price on shares of Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $79.36.
View Our Latest Analysis on BRKR
Bruker Trading Up 2.6 %
Bruker (NASDAQ:BRKR – Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.61 by ($0.01). The company had revenue of $864.40 million during the quarter, compared to analyst estimates of $866.46 million. Bruker had a net margin of 11.29% and a return on equity of 24.92%. The firm’s revenue for the quarter was up 16.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.74 earnings per share. As a group, equities analysts forecast that Bruker will post 2.61 EPS for the current year.
Bruker Company Profile
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Featured Articles
- Five stocks we like better than Bruker
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- What is a Bond Market Holiday? How to Invest and Trade
- Breakout Alert: Qualcomm Just Hit The Rally Button
- Most Volatile Stocks, What Investors Need to Know
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.